Oryzon to Present Updated AML Data at EHA Congress
Event summary
- Oryzon Genomics will present updated data from clinical trials of iadademstat for acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress in June.
- The company will also participate in Bio-Equity Europe, Foro Medcap, the Jefferies Healthcare Conference, the Spring European MidCap Event, and the BIO International Convention.
- Preliminary data from trials combining iadademstat with azacitidine and venetoclax showed a 100% overall response rate (ORR) in 1L AML.
- Oryzon is advancing a broader epigenetics pipeline, including ORY-4001 for CMT and ALS.
The big picture
Oryzon’s progress with iadademstat, particularly its combination therapies, positions it as a potential player in the competitive AML treatment landscape. The company’s reliance on investigator-initiated studies (IIS) and collaborations with institutions like OHSU and the NCI, while enabling rapid development, also introduces dependencies and potential IP complexities. The upcoming EHA presentation represents a key inflection point for the program’s future.
What we're watching
- Clinical Data
- The EHA presentation will be critical in assessing the continued efficacy and safety of iadademstat, particularly given the promising but early-stage data previously reported.
- Regulatory Path
- The success of ongoing trials and the potential for accelerated approval pathways will heavily influence Oryzon’s valuation, especially given the orphan drug designations for SCLC and AML.
- Pipeline Expansion
- How Oryzon balances its focus on iadademstat’s hematological and solid tumor applications, versus the broader epigenetics pipeline, will dictate long-term growth prospects.
Related topics